Patient Characteristics and Treatment Patterns with Macitentan in Pulmonary Arterial Hypertension: Insights from the OPUS Registry

被引:0
|
作者
Channick, R. [1 ]
Chin, K. [2 ]
Kim, N. [3 ]
Brand, M. [4 ]
Morganti, A. [4 ]
Selej, M. [5 ]
McLaughlin, V. [6 ]
机构
[1] Univ Calif Los Angeles, Los Angeles, CA USA
[2] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[3] Univ Calif San Diego, La Jolla, CA 92093 USA
[4] Actel Pharmaceut Ltd, Allschwil, Switzerland
[5] Actel Pharmaceut US Inc, San Francisco, CA USA
[6] Univ Michigan, Ann Arbor, MI 48109 USA
来源
关键词
D O I
10.1016/j.healun.2019.01.1245
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
1235
引用
收藏
页码:S489 / S490
页数:2
相关论文
共 50 条
  • [31] Pulmonary Arterial Hypertension Baseline Characteristics From the REVEAL Registry
    Badesch, David B.
    Raskob, Gary E.
    Elliott, C. Greg
    Krichman, Abby M.
    Farber, Harrison W.
    Frost, Adaani E.
    Barst, Robyn. J.
    Benza, Raymond L.
    Liou, Theodore G.
    Turner, Michelle
    Giles, Scott
    Feldkircher, Kathy
    Miller, Dave P.
    McGoon, Michael D.
    CHEST, 2010, 137 (02) : 376 - 387
  • [32] Macitentan in incident and prevalent pulmonary arterial hypertension (PAH): OPUS/OrPHeUS real-world data
    Melendres-Groves, Lana
    Channick, Richard
    Chin, Kelly
    Mclaughlin, Vallerie V.
    Flynn, Megan
    Ong, Rose
    Wetherill, Graham
    Kim, Nick H.
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [33] Tolerability of Switch to Macitentan from Bosentan in Pulmonary Arterial Hypertension
    Safdar, Zeenat
    Thakur, Aishwarya
    Frost, Adaani
    SOUTHERN MEDICAL JOURNAL, 2017, 110 (03) : 223 - 228
  • [34] Switch From Bosentan to Macitentan in Patients With Pulmonary Arterial Hypertension
    Gray, Carol
    Jones, Sharon
    Stewart, Jeffrey
    CHEST, 2015, 148 (04)
  • [36] Safety of macitentan for the treatment of pulmonary hypertension: Real-world experience from the OPsumit® USers Registry (OPUS) and OPsumit® Historical USers cohort (OrPHeUS)
    McLaughlin, Vallerie V.
    Channick, Richard
    Kim, Nick H.
    Frantz, Robert P.
    McConnell, John W.
    Melendres-Groves, Lana
    Miller, Chad
    Ravichandran, Ashwin
    Rodriguez-Lopez, Josanna
    Brand, Monika
    Leroy, Sandrine
    Wetherill, Graham
    Chin, Kelly M.
    PULMONARY CIRCULATION, 2022, 12 (04)
  • [37] Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
    Pulido, Tomas
    Adzerikho, Igor
    Channick, Richard N.
    Delcroix, Marion
    Galie, Nazzareno
    Ghofrani, Hossein-Ardeschir
    Jansa, Pavel
    Jing, Zhi-Cheng
    Le Brun, Franck-Olivier
    Mehta, Sanjay
    Mittelholzer, Camilla M.
    Perchenet, Loic
    Sastry, B. K. S.
    Sitbon, Olivier
    Souza, Rogerio
    Torbicki, Adam
    Zeng, Xiaofeng
    Rubin, Lewis J.
    Simonneau, Gerald
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (09): : 809 - 818
  • [38] Safety, efficacy, and clinical utility of macitentan in the treatment of pulmonary arterial hypertension
    Monaco, Thomas J.
    Davila, Carlos D.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 1675 - 1681
  • [39] Early Experiences with Macitentan Therapy for the Treatment of Pulmonary Arterial Hypertension (PAH)
    Minnock, C.
    Murray, M.
    Gaine, S.
    IRISH JOURNAL OF MEDICAL SCIENCE, 2014, 183 : S517 - S517
  • [40] Diagnostic delay in pulmonary arterial hypertension: Insights from the Australian and New Zealand pulmonary hypertension registry
    Khou, Victor
    Anderson, James J.
    Strange, Geoff
    Corrigan, Carolyn
    Collins, Nicholas
    Celermajer, David S.
    Dwyer, Nathan
    Feenstra, John
    Horrigan, Mark
    Keating, Dominic
    Kotlyar, Eugene
    Lavender, Melanie
    McWilliams, Tanya J.
    Steele, Peter
    Weintraub, Robert
    Whitford, Helen
    Whyte, Ken
    Williams, Trevor J.
    Wrobel, Jeremy P.
    Keogh, Anne
    Lau, Edmund M.
    RESPIROLOGY, 2020, 25 (08) : 863 - 871